{
    "info": {
        "nct_id": "NCT04548648",
        "official_title": "LCCC1841: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas",
        "inclusion_criteria": "1. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty.\n2. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).\n3. Age ≥18 years at the time of consent.\n4. Subject has adequate performance status as defined by The Eastern Cooperative Oncology Group (ECOG) of ≤ 2\n5. Subject has histological confirmation of biopsy-proven central nervous system (CNS) lymphoma or magnetic resonance imaging (MRI) findings consistent with CNS lymphoma if biopsy is not possible (due to inaccessible location). Subjects with intra-ocular lymphoma will not be excluded as long as there is also parenchymal disease.\n6. Subject has B-cell Non-Hodgkin Lymphoma.\n7. Subject has no evidence of systemic involvement of lymphoma confirmed by computerized tomography (CT) or positron emission tomography (PET)-CT imaging within 28 days prior to first dosing in the study.\n8. Subject must have received at least one prior line of chemotherapy for primary or secondary CNS lymphoma.\n9. Subject has adequate organ function as demonstrated by: System Laboratory Value Hematological* Absolute Neutrophil Count (ANC) ≥ 1 x 109/L Platelets ≥ 75 x 109/L Renal* Calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault formula (Appendix B) Hepatic* Bilirubin ≤ 1.5 × upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated bilirubin is <1.5× ULN) Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) ≤ 2 × ULN (in the absence of lupus anticoagulant)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Subjects meeting any of the following exclusion criteria will not be able to participate in this study.\n\n1. Prior cancer treatment that was completed less than 14 days prior to Day 1 of study dosing or if subject has not recovered from all reversible acute toxic effects of the regimen to grade ≤1 or baseline.\n2. Prior brain radiotherapy under the following conditions:\n\n   * Whole-brain radiotherapy (WBRT) that was completed less than 28 days prior to Day 1 of study dosing\n   * Stereotactic radiosurgery (SRS) that was competed less than 14 days prior to Day 1 of study dosing.\n3. Currently participating in or has participated in a study of an investigational agent within 28 days of first dosing with study treatment.\n4. Subject is pregnant or breastfeeding.\n5. Subject has active cerebrospinal fluid (CSF) involvement that requires ongoing intrathecal chemotherapy\n6. Previous exposure to a Bruton Tyrosine Kinase (BTK) inhibitor.\n7. Subjects with severe hepatic insufficiency, as defined by Child-Pugh Score > 6.\n8. Subject is receiving prohibited medications or treatments as listed in the protocol that cannot be discontinued/replaced by an alternative therapy.\n9. Subject requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 14 days of first dose of study drug. Subjects requires or is taking direct oral anticoagulants within 7 days of first dose of study drug.\n10. Subject requires treatment with proton pump inhibitors. Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.\n11. Subject is currently receiving any chemotherapy, anticancer immunotherapy.\n12. Subject has clinically significant cardiovascular disease such as ventricular dysfunction, symptomatic coronary artery disease, uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association (NYHA) Functional Classification at screening. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study.\n13. Subject has familial short QT syndrome.\n14. Subject has a history of malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass that is likely to affect absorption.\n15. Subject has a known history of infection with HIV or any uncontrolled active significant infection.\n16. Subject has a known history of drug-specific hypersensitivity or anaphylaxis to acalabrutinib (including active ingredient or excipient components).\n17. Subject has active bleeding or history of bleeding diathesis.\n18. Subject has a history of uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).\n19. Subject has a history of significant cerebrovascular disease/event, including stroke or intracranial hemorrhage, within 6 months before the first dose of acalabrutinib.\n20. Subject had major surgical procedure within 28 days of first dose of acalabrutinib.\n21. Subject who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative PCR result before randomization and must be willing to undergo DNA PCR testing during the study. Subjects who are core antibody positive and viral load negative must receive entecavir Those who are HbsAg-positive, or hepatitis B PCR positive will be excluded.\n22. Subjects who are hepatitis C antibody positive must have a negative polymerase chain reaction (PCR) result. Those who are hepatitis C PCR positive will be excluded.\n23. Subjects with evidence of disease that investigator decides that is not suitable to enroll in the study.\n24. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML).\n25. Received a live virus vaccination within 28 days of first dose of study drug.\n26. Any active significant infection.\n27. Concurrent participation in another therapeutic clinical trial.\n28. Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the subject's safety or put the study at risk.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subject has adequate performance status as defined by The Eastern Cooperative Oncology Group (ECOG) of ≤ 2",
            "criterions": [
                {
                    "exact_snippets": "adequate performance status ... The Eastern Cooperative Oncology Group (ECOG) of ≤ 2",
                    "criterion": "performance status (ECOG)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ECOG"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Age ≥18 years at the time of consent.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 years at the time of consent.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value at time of consent",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Subject has B-cell Non-Hodgkin Lymphoma.",
            "criterions": [
                {
                    "exact_snippets": "Subject has B-cell Non-Hodgkin Lymphoma.",
                    "criterion": "B-cell Non-Hodgkin Lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Subject must have received at least one prior line of chemotherapy for primary or secondary CNS lymphoma.",
            "criterions": [
                {
                    "exact_snippets": "Subject must have received at least one prior line of chemotherapy for primary or secondary CNS lymphoma.",
                    "criterion": "prior chemotherapy for CNS lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": [
                                "primary CNS lymphoma",
                                "secondary CNS lymphoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand the purpose and risks of the study",
                    "criterion": "cognitive ability to understand study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "provide signed and dated informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed and dated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "authorization to use protected health information (in accordance with national and local patient privacy regulations)",
                    "criterion": "authorization to use protected health information",
                    "requirements": [
                        {
                            "requirement_type": "authorization",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules and tablets without difficulty.",
            "criterions": [
                {
                    "exact_snippets": "Willing and able to participate in all required evaluations and procedures in this study protocol",
                    "criterion": "participation in study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "swallowing capsules and tablets without difficulty",
                    "criterion": "swallowing capsules and tablets",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "difficulty",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subject has histological confirmation of biopsy-proven central nervous system (CNS) lymphoma or magnetic resonance imaging (MRI) findings consistent with CNS lymphoma if biopsy is not possible (due to inaccessible location). Subjects with intra-ocular lymphoma will not be excluded as long as there is also parenchymal disease.",
            "criterions": [
                {
                    "exact_snippets": "histological confirmation of biopsy-proven central nervous system (CNS) lymphoma",
                    "criterion": "central nervous system (CNS) lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "histological confirmation of biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "magnetic resonance imaging (MRI) findings consistent with CNS lymphoma if biopsy is not possible (due to inaccessible location)",
                    "criterion": "central nervous system (CNS) lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "MRI findings consistent with CNS lymphoma"
                        },
                        {
                            "requirement_type": "biopsy_possibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with intra-ocular lymphoma will not be excluded as long as there is also parenchymal disease",
                    "criterion": "intra-ocular lymphoma with parenchymal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Subject has no evidence of systemic involvement of lymphoma confirmed by computerized tomography (CT) or positron emission tomography (PET)-CT imaging within 28 days prior to first dosing in the study.",
            "criterions": [
                {
                    "exact_snippets": "no evidence of systemic involvement of lymphoma",
                    "criterion": "systemic involvement of lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed by computerized tomography (CT) or positron emission tomography (PET)-CT imaging",
                    "criterion": "systemic involvement of lymphoma confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "computerized tomography (CT)",
                                "positron emission tomography (PET)-CT imaging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within 28 days prior to first dosing in the study",
                    "criterion": "timing of imaging",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to first dosing"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "18. Subject has a history of uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).",
            "criterions": [
                {
                    "exact_snippets": "history of uncontrolled autoimmune hemolytic anemia (AIHA)",
                    "criterion": "autoimmune hemolytic anemia (AIHA)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... idiopathic thrombocytopenic purpura (ITP)",
                    "criterion": "idiopathic thrombocytopenic purpura (ITP)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Subject has a known history of infection with HIV or any uncontrolled active significant infection.",
            "criterions": [
                {
                    "exact_snippets": "known history of infection with HIV",
                    "criterion": "HIV infection history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any uncontrolled active significant infection",
                    "criterion": "significant infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stereotactic radiosurgery (SRS) that was competed less than 14 days prior to Day 1 of study dosing.",
            "criterions": [
                {
                    "exact_snippets": "Stereotactic radiosurgery (SRS) that was competed less than 14 days prior to Day 1 of study dosing.",
                    "criterion": "stereotactic radiosurgery (SRS)",
                    "requirements": [
                        {
                            "requirement_type": "time since completion",
                            "expected_value": {
                                "operator": "<",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Subject has familial short QT syndrome.",
            "criterions": [
                {
                    "exact_snippets": "Subject has familial short QT syndrome.",
                    "criterion": "familial short QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Subject has clinically significant cardiovascular disease such as ventricular dysfunction, symptomatic coronary artery disease, uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association (NYHA) Functional Classification at screening. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study.",
            "criterions": [
                {
                    "exact_snippets": "clinically significant cardiovascular disease such as ventricular dysfunction",
                    "criterion": "ventricular dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiovascular disease such as ... symptomatic coronary artery disease",
                    "criterion": "symptomatic coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiovascular disease such as ... uncontrolled or symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiovascular disease such as ... congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiovascular disease such as ... myocardial infarction within 6 months of screening",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "reference_event",
                            "expected_value": "screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "any Class 3 or 4 cardiac disease as defined by the New York Heart Association (NYHA) Functional Classification at screening",
                    "criterion": "cardiac disease (NYHA Functional Classification)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "Class 3",
                                "Class 4"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study",
                    "criterion": "atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "controlled"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Subject is receiving prohibited medications or treatments as listed in the protocol that cannot be discontinued/replaced by an alternative therapy.",
            "criterions": [
                {
                    "exact_snippets": "Subject is receiving prohibited medications or treatments as listed in the protocol that cannot be discontinued/replaced by an alternative therapy.",
                    "criterion": "prohibited medications or treatments",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to discontinue or replace",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. Subjects who are hepatitis C antibody positive must have a negative polymerase chain reaction (PCR) result. Those who are hepatitis C PCR positive will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "hepatitis C antibody positive must have a negative polymerase chain reaction (PCR) result",
                    "criterion": "hepatitis C infection status",
                    "requirements": [
                        {
                            "requirement_type": "antibody status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "PCR result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C PCR positive will be excluded",
                    "criterion": "hepatitis C infection status",
                    "requirements": [
                        {
                            "requirement_type": "PCR result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Subject had major surgical procedure within 28 days of first dose of acalabrutinib.",
            "criterions": [
                {
                    "exact_snippets": "Subject had major surgical procedure within 28 days of first dose of acalabrutinib.",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relation to acalabrutinib dosing",
                            "expected_value": "within 28 days of first dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Subject is currently receiving any chemotherapy, anticancer immunotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Subject is currently receiving any chemotherapy",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject is currently receiving any ... anticancer immunotherapy",
                    "criterion": "anticancer immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Subjects with evidence of disease that investigator decides that is not suitable to enroll in the study.",
            "criterions": [
                {
                    "exact_snippets": "evidence of disease",
                    "criterion": "evidence of disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "investigator decides that is not suitable to enroll in the study",
                    "criterion": "investigator assessment of suitability for enrollment",
                    "requirements": [
                        {
                            "requirement_type": "suitability for enrollment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Subject requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 14 days of first dose of study drug. Subjects requires or is taking direct oral anticoagulants within 7 days of first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Subject requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 14 days of first dose of study drug",
                    "criterion": "anticoagulation with warfarin or equivalent vitamin K antagonists",
                    "requirements": [
                        {
                            "requirement_type": "use within days of first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects requires or is taking direct oral anticoagulants within 7 days of first dose of study drug",
                    "criterion": "direct oral anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "use within days of first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subject is pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Subject is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "27. Concurrent participation in another therapeutic clinical trial.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent participation in another therapeutic clinical trial.",
                    "criterion": "participation in another therapeutic clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "concurrent participation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subject has active cerebrospinal fluid (CSF) involvement that requires ongoing intrathecal chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "active cerebrospinal fluid (CSF) involvement",
                    "criterion": "cerebrospinal fluid (CSF) involvement",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requires ongoing intrathecal chemotherapy",
                    "criterion": "intrathecal chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for ongoing treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "25. Received a live virus vaccination within 28 days of first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Received a live virus vaccination within 28 days of first dose of study drug.",
                    "criterion": "live virus vaccination",
                    "requirements": [
                        {
                            "requirement_type": "time since vaccination before first dose of study drug",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "26. Any active significant infection.",
            "criterions": [
                {
                    "exact_snippets": "Any active significant infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Subject has active bleeding or history of bleeding diathesis.",
            "criterions": [
                {
                    "exact_snippets": "active bleeding",
                    "criterion": "bleeding",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Subject has a history of malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass that is likely to affect absorption.",
            "criterions": [
                {
                    "exact_snippets": "history of malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "disease significantly affecting gastrointestinal function",
                    "criterion": "disease affecting gastrointestinal function",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significantly affecting"
                        }
                    ]
                },
                {
                    "exact_snippets": "resection of the stomach or small bowel",
                    "criterion": "resection of the stomach or small bowel",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "partial or complete bowel obstruction",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "partial",
                                "complete"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "gastric restrictions and bariatric surgery, such as gastric bypass that is likely to affect absorption",
                    "criterion": "gastric restrictions and bariatric surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "likelihood to affect absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior brain radiotherapy under the following conditions:",
            "criterions": [
                {
                    "exact_snippets": "Prior brain radiotherapy",
                    "criterion": "brain radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Currently participating in or has participated in a study of an investigational agent within 28 days of first dosing with study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Currently participating in ... a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent within 28 days of first dosing with study treatment",
                    "criterion": "prior participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Whole-brain radiotherapy (WBRT) that was completed less than 28 days prior to Day 1 of study dosing",
            "criterions": [
                {
                    "exact_snippets": "Whole-brain radiotherapy (WBRT) that was completed less than 28 days prior to Day 1 of study dosing",
                    "criterion": "whole-brain radiotherapy (WBRT)",
                    "requirements": [
                        {
                            "requirement_type": "completion time before study dosing",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "28. Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the subject's safety or put the study at risk.",
            "criterions": [
                {
                    "exact_snippets": "Current life-threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "life-threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current life-threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current life-threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the Investigator's opinion, could compromise the subject's safety or put the study at risk",
                    "criterion": "investigator's opinion of risk",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Subjects with severe hepatic insufficiency, as defined by Child-Pugh Score > 6.",
            "criterions": [
                {
                    "exact_snippets": "severe hepatic insufficiency",
                    "criterion": "hepatic insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "Child-Pugh Score > 6",
                    "criterion": "Child-Pugh Score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Subject requires treatment with proton pump inhibitors. Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.",
            "criterions": [
                {
                    "exact_snippets": "Subject requires treatment with proton pump inhibitors.",
                    "criterion": "proton pump inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "requirement for treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment",
                    "criterion": "use of H2-receptor antagonists or antacids instead of proton pump inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "current medication",
                            "expected_value": [
                                "H2-receptor antagonists",
                                "antacids"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Previous exposure to a Bruton Tyrosine Kinase (BTK) inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Previous exposure to a Bruton Tyrosine Kinase (BTK) inhibitor.",
                    "criterion": "Bruton Tyrosine Kinase (BTK) inhibitor exposure",
                    "requirements": [
                        {
                            "requirement_type": "history of exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML).",
            "criterions": [
                {
                    "exact_snippets": "History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)",
                    "criterion": "progressive multifocal leukoencephalopathy (PML)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current/ongoing diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Subject has a known history of drug-specific hypersensitivity or anaphylaxis to acalabrutinib (including active ingredient or excipient components).",
            "criterions": [
                {
                    "exact_snippets": "known history of drug-specific hypersensitivity or anaphylaxis to acalabrutinib (including active ingredient or excipient components)",
                    "criterion": "drug-specific hypersensitivity to acalabrutinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known history of ... anaphylaxis to acalabrutinib (including active ingredient or excipient components)",
                    "criterion": "anaphylaxis to acalabrutinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Subject has a history of significant cerebrovascular disease/event, including stroke or intracranial hemorrhage, within 6 months before the first dose of acalabrutinib.",
            "criterions": [
                {
                    "exact_snippets": "history of significant cerebrovascular disease/event, including stroke or intracranial hemorrhage, within 6 months before the first dose of acalabrutinib",
                    "criterion": "significant cerebrovascular disease/event",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of significant cerebrovascular disease/event, including stroke",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of significant cerebrovascular disease/event, including ... intracranial hemorrhage",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior cancer treatment that was completed less than 14 days prior to Day 1 of study dosing or if subject has not recovered from all reversible acute toxic effects of the regimen to grade ≤1 or baseline.",
            "criterions": [
                {
                    "exact_snippets": "Prior cancer treatment that was completed less than 14 days prior to Day 1 of study dosing",
                    "criterion": "prior cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "completion interval before study dosing",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subject has not recovered from all reversible acute toxic effects of the regimen to grade ≤1 or baseline",
                    "criterion": "recovery from reversible acute toxic effects of prior cancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": "baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. Subject who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative PCR result before randomization and must be willing to undergo DNA PCR testing during the study. Subjects who are core antibody positive and viral load negative must receive entecavir Those who are HbsAg-positive, or hepatitis B PCR positive will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "hepatitis B core antibody (anti-HBc) positive",
                    "criterion": "hepatitis B core antibody (anti-HBc)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B surface antigen (HBsAg) negative",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "negative PCR result before randomization",
                    "criterion": "hepatitis B PCR result before randomization",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to undergo DNA PCR testing during the study",
                    "criterion": "willingness to undergo DNA PCR testing during the study",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "core antibody positive and viral load negative must receive entecavir",
                    "criterion": "entecavir prophylaxis",
                    "requirements": [
                        {
                            "requirement_type": "requirement for entecavir",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HbsAg-positive, or hepatitis B PCR positive will be excluded",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "HbsAg-positive, or hepatitis B PCR positive will be excluded",
                    "criterion": "hepatitis B PCR result",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "9. Subject has adequate organ function as demonstrated by: System Laboratory Value Hematological* Absolute Neutrophil Count (ANC) ≥ 1 x 109/L Platelets ≥ 75 x 109/L Renal* Calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault formula (Appendix B) Hepatic* Bilirubin ≤ 1.5 × upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated bilirubin is <1.5× ULN) Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) ≤ 2 × ULN (in the absence of lupus anticoagulant)",
            "criterions": [
                {
                    "exact_snippets": "Absolute Neutrophil Count (ANC) ≥ 1 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelets ≥ 75 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                },
                {
                    "exact_snippets": "Bilirubin ≤ 1.5 × upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated bilirubin is <1.5× ULN",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated bilirubin is <1.5× ULN"
                        }
                    ]
                },
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ≤ 2.5 × ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ≤ 2.5 × ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "International Normalized Ratio (INR) or Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) ≤ 2 × ULN (in the absence of lupus anticoagulant)",
                    "criterion": "coagulation (INR, PT, aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "in the absence of lupus anticoagulant"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "Subjects meeting any of the following exclusion criteria will not be able to participate in this study.",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}